IGM Biosciences is undergoing a strategic pivot to focus on T cell engagers for autoimmune diseases, resulting in a reduction in force and the resignation of key executives, including the CEO, with new leadership appointed. The company expects its cash reserves to fund operations into 2027 as it shifts its pipeline and continues collaboration with Sanofi.